|
CA1223831A
(en)
|
1982-06-23 |
1987-07-07 |
Dean Engelhardt |
Modified nucleotides, methods of preparing and utilizing and compositions containing the same
|
|
CA2259123C
(en)
*
|
1996-07-01 |
2003-10-21 |
Lorus Therapeutics Inc. |
Oligonucleotides from the untranslated regions of ribonucleotide reductase and their use to modulate cell growth
|
|
US6593305B1
(en)
|
1996-08-02 |
2003-07-15 |
Genesense Technologies Inc. |
Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
|
|
ES2222577T3
(es)
*
|
1997-03-19 |
2005-02-01 |
Genesense Technologies Inc. |
Supresion de la malignidad utilizando la ribonucleotido reductasa r1.
|
|
US6835395B1
(en)
|
1997-05-14 |
2004-12-28 |
The University Of British Columbia |
Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
|
|
US6610539B1
(en)
*
|
1997-07-10 |
2003-08-26 |
Genesense Technologies, Inc. |
Antisense oligonucleotide sequences as inhibitors of microorganisms
|
|
EP1584681A3
(en)
*
|
1997-07-10 |
2005-11-09 |
GeneSense Technologies Inc. |
Antisense oligonucleotide sequences as inhibitors of microorganisms
|
|
US6506559B1
(en)
*
|
1997-12-23 |
2003-01-14 |
Carnegie Institute Of Washington |
Genetic inhibition by double-stranded RNA
|
|
AUPP249298A0
(en)
|
1998-03-20 |
1998-04-23 |
Ag-Gene Australia Limited |
Synthetic genes and genetic constructs comprising same I
|
|
BRPI9908967B1
(pt)
*
|
1998-03-20 |
2017-05-30 |
Benitec Australia Ltd |
processos para reprimir, retardar ou de outro modo reduzir a expressão de um gene alvo em uma célula de planta
|
|
WO2000044914A1
(en)
*
|
1999-01-28 |
2000-08-03 |
Medical College Of Georgia Research Institute, Inc. |
Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
|
|
US6121000A
(en)
*
|
1999-02-11 |
2000-09-19 |
Genesense Technologies, Inc. |
Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
|
|
US20040138168A1
(en)
*
|
1999-04-21 |
2004-07-15 |
Wyeth |
Methods and compositions for inhibiting the function of polynucleotide sequences
|
|
US6642033B1
(en)
*
|
1999-07-20 |
2003-11-04 |
V.I. Technologies, Inc. |
Nucleic acids for detecting parvovirus and methods of using same
|
|
US6423885B1
(en)
|
1999-08-13 |
2002-07-23 |
Commonwealth Scientific And Industrial Research Organization (Csiro) |
Methods for obtaining modified phenotypes in plant cells
|
|
CN1301816A
(zh)
*
|
1999-12-27 |
2001-07-04 |
上海博德基因开发有限公司 |
一种新的多肽——核苷酸还原酶10和编码这种多肽的多核苷酸
|
|
JP2003527856A
(ja)
*
|
2000-03-17 |
2003-09-24 |
ベニテック オーストラリア リミテッド |
遺伝子のサイレンシング
|
|
CA2369944A1
(en)
*
|
2001-01-31 |
2002-07-31 |
Nucleonics Inc. |
Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
|
|
DE10131148A1
(de)
*
|
2001-06-28 |
2003-01-16 |
I P L Internat Pharmaceutics L |
Xenogene Oligo- oder/und Polyribonukleotide als Mittel zur Behandlung von malignen Tumoren
|
|
JP2006518344A
(ja)
*
|
2003-02-10 |
2006-08-10 |
ジェネセンス テクノロジーズ インク |
リボヌクレオチド還元酵素ｒ２を指向するアンチセンスオリゴヌクレオチドおよび癌の治療におけるこれらの使用
|
|
AU2003225410A1
(en)
*
|
2003-03-21 |
2004-10-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
|
CA2526393A1
(en)
*
|
2003-05-21 |
2004-12-02 |
Genesense Technologies Inc. |
Antisense oligonucleotides directed to ribonucleotide reductase r1 and uses thereof in the treatment of cancer
|
|
WO2004106518A1
(en)
*
|
2003-05-31 |
2004-12-09 |
Genesense Technologies Inc. |
Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treatment of cancer
|
|
KR20060116825A
(ko)
|
2003-10-23 |
2006-11-15 |
일루미겐 바이오사이언시스, 인코포레이티드 |
바이러스 감염에 대한 저항성과 관련된 유전자인ｏａｓ1에서의 돌연변이의 검출
|
|
CA2553211A1
(en)
*
|
2004-01-12 |
2005-07-21 |
Genesense Technologies Inc. |
Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in combination therapies for the treatment of cancer
|
|
AU2005247319B2
(en)
*
|
2004-04-28 |
2011-12-01 |
Molecules For Health, Inc. |
Methods for treating or preventing restenosis and other vascular proliferative disorders
|
|
WO2005111211A2
(en)
*
|
2004-05-14 |
2005-11-24 |
Rosetta Genomics Ltd. |
Micronas and uses thereof
|
|
US7968762B2
(en)
*
|
2004-07-13 |
2011-06-28 |
Van Andel Research Institute |
Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF)
|
|
WO2006017932A1
(en)
*
|
2004-08-18 |
2006-02-23 |
Genesense Technologies Inc. |
Small interfering rna molecules against ribonucleotide reductase and uses thereof
|
|
US20060185027A1
(en)
*
|
2004-12-23 |
2006-08-17 |
David Bartel |
Systems and methods for identifying miRNA targets and for altering miRNA and target expression
|
|
ATE541928T1
(de)
*
|
2005-03-31 |
2012-02-15 |
Calando Pharmaceuticals Inc |
Inhibitoren der untereinheit 2 der ribonukleotidreduktase und ihre verwendungen
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
TW200808739A
(en)
|
2006-04-06 |
2008-02-16 |
Novartis Vaccines & Diagnostic |
Quinazolines for PDK1 inhibition
|
|
EP2030615A3
(en)
*
|
2007-08-13 |
2009-12-02 |
ELFORD, Howard L. |
Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
|
|
US20100204305A1
(en)
*
|
2007-12-11 |
2010-08-12 |
Lorus Therapeutics Inc. |
Small interfering rna molecules against ribonucleotide reductase and uses thereof
|
|
KR20100093129A
(ko)
|
2007-12-20 |
2010-08-24 |
노파르티스 아게 |
Ｐｉ ３ 키나제 억제제로서 사용되는 티아졸 유도체
|
|
WO2010027279A2
(en)
*
|
2008-09-04 |
2010-03-11 |
Genesis Research And Development Corporation Limited |
Compositions and methods for the treatment and prevention of neoplastic disorders
|
|
EP2350264A4
(en)
|
2008-11-06 |
2012-08-29 |
Univ Johns Hopkins |
TREATMENT OF CHRONIC INFLAMMATION OF THE RESPIRATORY TRACT
|
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
|
WO2012052258A1
(en)
*
|
2010-10-18 |
2012-04-26 |
Arrowhead Research Corporation |
Compositions and methods for inhibiting expression of rrm2 genes
|
|
CA2825605C
(en)
|
2011-01-31 |
2019-05-07 |
Novartis Ag |
Heterocyclic derivatives
|
|
PH12014500912A1
(en)
|
2011-10-28 |
2014-06-09 |
Novartis Ag |
Novel purine derivatives and their use in the treatment of disease
|
|
SG11201406550QA
(en)
|
2012-05-16 |
2014-11-27 |
Novartis Ag |
Dosage regimen for a pi-3 kinase inhibitor
|
|
KR20160095035A
(ko)
|
2013-12-06 |
2016-08-10 |
노파르티스 아게 |
알파-이소형 선택성 포스파티딜이노시톨 3-키나제 억제제를 위한 투여 요법
|
|
KR20180073674A
(ko)
|
2015-11-02 |
2018-07-02 |
노파르티스 아게 |
포스파티딜이노시톨 3-키나제 억제제에 대한 투여 요법
|
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|